Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

3,650JPY
12:12am GMT
Change (% chg)

¥60 (+1.67%)
Prev Close
¥3,590
Open
¥3,690
Day's High
¥3,695
Day's Low
¥3,645
Volume
149,600
Avg. Vol
1,476,597
52-wk High
¥4,015
52-wk Low
¥2,359

4519.T

Chart for 4519.T

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)

Overall

Beta: 0.62
Market Cap(Mil.): ¥1,992,482.00
Shares Outstanding(Mil.): 559.69
Dividend: 26.00
Yield (%): 1.35

Financials

  4519.T Industry Sector
P/E (TTM): 38.12 38.99 40.21
EPS (TTM): 93.38 -- --
ROI: 8.53 17.01 16.34
ROE: 8.73 17.53 17.27
Search Stocks

REFILE-TABLE-Chugai Pharm -2014 group results (IFRS)

(Adds company forecast) Jan 28 - Chugai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to Dec 31, 2014 Dec 31, 2013 Dec 31, 2015 LATEST YEAR-AGO COMPANY RESULTS RESULT FORECAST Sales 461.11 423.65 486.

28 Jan 2015

REFILE-TABLE-Chugai Pharm -9-MTH group results (IFRS)

(Adds company forecast) Oct 24 - Chugai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Sep 30, 2014 Sep 30, 2013 Dec 31, 2014 LATEST YEAR-AGO COMPANY RESULTS RESULT FORECAST Sales 333.43 306

24 Oct 2014

Roche rules out mega deals, open to smaller ones - paper

ZURICH - Roche has ruled out major "double-digit billion" purchases but is open to smaller deals, the Swiss drugmaker's chairman said in an interview with a German newspaper published on Thursday.

04 Sep 2014

Roche rules out mega deals, open to smaller ones - paper

ZURICH, Sept 4 - Roche has ruled out major "double-digit billion" purchases but is open to smaller deals, the Swiss drugmaker's chairman said in an interview with a German newspaper published on Thursday.

04 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: MarketLine (a Datamonitor Company)
£114.00
Provider: GlobalData
£81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks